{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T20:42:24Z","timestamp":1776458544675,"version":"3.51.2"},"reference-count":36,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/501100013795","name":"Fujian Medical University","doi-asserted-by":"publisher","award":["XRCZX2020003"],"award-info":[{"award-number":["XRCZX2020003"]}],"id":[{"id":"10.13039\/501100013795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J01283"],"award-info":[{"award-number":["2022J01283"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100872"],"award-info":[{"award-number":["82100872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>This study aimed to evaluate lactic acidosis (LA) risk when using metformin combined with histamine H2 receptor inhibitors (H2RI) in patients with renal failure (RF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>This study analyzed FDA Adverse Event Reporting System data (2012Q4 to 2022Q4) to characterize reports of LA associated with metformin alone or combined with H2RI. Using a disproportionality approach, LA risk signal in the overall population and in patients with RF was assessed. A physiologically based pharmacokinetic (PBPK) model was developed to predict metformin and cimetidine pharmacokinetic changes following conventional doses of the combinations in patients with various degrees of RF. To explore its correlation with LA risk, a peak plasma metformin concentration of 3 mg\/L was considered the threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Following the 2016 U.S. Food and Drug Administration metformin approval for mild-to-moderate RF, the percentage of patients with RF reporting LA associated with metformin combined with H2RI increased. Disproportionality analysis showed reported LA risk signal associated with metformin and cimetidine in the overall population within the study timeframe only. Furthermore, with PBPK simulations, for metformin (1,000 mg b.i.d.) with cimetidine (300 mg q.i.d. or 400 mg b.i.d.) in stage 1 of chronic kidney disease, metformin (1,000 mg b.i.d.) with cimetidine (300 mg q.i.d. or 400 mg b.i.d. or 800 mg q.d.) in stage 2, and most combinations in stage 3, the peak plasma metformin concentrations exceeded the 3 mg\/L threshold.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Metformin combined with cimetidine at conventional doses may cause LA in patients with mild-to-moderate RF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc23-1344","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T13:44:04Z","timestamp":1699623844000},"page":"144-150","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":8,"title":["Metformin-Cimetidine Drug Interaction and Risk of Lactic Acidosis in Renal Failure: A Pharmacovigilance-Pharmacokinetic Appraisal"],"prefix":"10.2337","volume":"47","author":[{"given":"Wenhuo","family":"Xie","sequence":"first","affiliation":[{"name":"1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbin","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghua","family":"Kong","sequence":"additional","affiliation":[{"name":"1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[{"name":"2Department of Rehabilitation Medicine, School of Health, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaping","family":"Zheng","sequence":"additional","affiliation":[{"name":"2Department of Rehabilitation Medicine, School of Health, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-3073","authenticated-orcid":false,"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"2023122019552461700_B1","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin in 2019","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"},{"key":"2023122019552461700_B2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"2023122019552461700_B3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s40264-019-00854-x","article-title":"The\u00a0association between metformin therapy and lactic acidosis","volume":"42","author":"Kuan","year":"2019","journal-title":"Drug Saf"},{"key":"2023122019552461700_B4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"},{"key":"2023122019552461700_B5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1124\/pr.118.015578","article-title":"Organic cation transporters in health and disease","volume":"72","author":"Koepsell","year":"2020","journal-title":"Pharmacol Rev"},{"key":"2023122019552461700_B6","first-page":"CD002967","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","volume":"2010","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2023122019552461700_B7","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"2023122019552461700_B8","author":"U.S. Food and Drug Administration"},{"key":"2023122019552461700_B9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s40262-015-0270-6","article-title":"A comprehensive review of drug-drug interactions with metformin","volume":"54","author":"Stage","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2023122019552461700_B10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1476-5381.2010.01052.x","article-title":"Double-transfected MDCK cells expressing human OCT1\/MATE1 or OCT2\/MATE1: determinants of uptake and transcellular translocation of organic cations","volume":"163","author":"K\u00f6nig","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2023122019552461700_B11","first-page":"70","author":"Burt","year":"2016"},{"key":"2023122019552461700_B12","doi-asserted-by":"crossref","first-page":"e0189521","DOI":"10.1371\/journal.pone.0189521","article-title":"Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine","volume":"12","author":"Meyer","year":"2017","journal-title":"PLoS One"},{"key":"2023122019552461700_B13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-015-0346-3","article-title":"The effect of famotidine, a MATE1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin","volume":"55","author":"Hibma","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"2023122019552461700_B14","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/psp4.12398","article-title":"Physiologically-based pharmacokinetic modeling analysis for quantitative prediction of renal transporter-mediated interactions between metformin and cimetidine","volume":"8","author":"Nishiyama","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2023122019552461700_B15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/11588310-000000000-00000","article-title":"Establishment of a database of metformin plasma concentrations and erythrocyte levels in normal and emergency situations","volume":"31","author":"Lalau","year":"2011","journal-title":"Clin Drug Investig"},{"key":"2023122019552461700_B16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/dme.12959","article-title":"Unexpectedly long half-life of metformin elimination in cases of metformin accumulation","volume":"33","author":"Kajbaf","year":"2016","journal-title":"Diabet Med"},{"key":"2023122019552461700_B17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/bcp.14394","article-title":"Understanding the association between metformin plasma concentrations and lactate","volume":"87","author":"Kuan","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2023122019552461700_B18","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40262-020-00896-w","article-title":"A comprehensive whole-body physiologically based pharmacokinetic drug-drug-gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals","volume":"59","author":"Hanke","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2023122019552461700_B19","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40264-022-01210-2","article-title":"Anti-tumor necrosis factor-alpha therapy and hypoglycemia: a real-world pharmacovigilance analysis","volume":"45","author":"Zhou","year":"2022","journal-title":"Drug Saf"},{"key":"2023122019552461700_B20","author":"Jiang","year":"2014"},{"key":"2023122019552461700_B21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"2023122019552461700_B22","doi-asserted-by":"crossref","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"2023122019552461700_B23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023122019552461700_B24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023122019552461700_B25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","article-title":"Comparison of signal detection algorithms based on frequency statistical model for drug-drug interaction using spontaneous reporting systems","volume":"37","author":"Noguchi","year":"2020","journal-title":"Pharm Res"},{"key":"2023122019552461700_B26","author":"Noguchi","year":"2020"},{"key":"2023122019552461700_B27","doi-asserted-by":"crossref","first-page":"833679","DOI":"10.3389\/fphar.2022.833679","article-title":"Acute kidney injury and drugs prescribed for COVID-19 in diabetes patients: a real-world disproportionality analysis","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Pharmacol"},{"key":"2023122019552461700_B28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/cpt.1693","article-title":"Physiologically-based pharmacokinetic models for evaluating membrane transporter mediated\u00a0drug-drug interactions: current capabilities, case studies, future opportunities, and recommendations","volume":"107","author":"Taskar","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2023122019552461700_B29","doi-asserted-by":"crossref","first-page":"107541","DOI":"10.1016\/j.pharmthera.2020.107541","article-title":"Physiologically-based pharmacokinetic models for children: Starting to reach maturation?","volume":"211","author":"Verscheijden","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2023122019552461700_B30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s00125-023-05898-4","article-title":"Significant impact of time-of-day variation on metformin pharmacokinetics","volume":"66","author":"T\u00fcrk","year":"2023","journal-title":"Diabetologia"},{"key":"2023122019552461700_B31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"2023122019552461700_B32","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.2337\/dc23-S011","article-title":"11. Chronic kidney disease and risk management: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2023122019552461700_B33","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"2023122019552461700_B34","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2337\/diacare.26.8.2471","article-title":"Case study: metformin-associated lactic acidosis: could orlistat be relevant?","volume":"26","author":"Dawson","year":"2003","journal-title":"Diabetes Care"},{"key":"2023122019552461700_B35","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/SMJ.0b013e3181e6363b","article-title":"Cimetidine-induced lactic acidosis and acute pancreatitis","volume":"103","author":"Boehm","year":"2010","journal-title":"South Med J"},{"key":"2023122019552461700_B36","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.2169\/internalmedicine.52.0697","article-title":"Severe lactic acidosis and acute pancreatitis associated with cimetidine in a patient with type 2 diabetes mellitus taking metformin","volume":"52","author":"Seo","year":"2013","journal-title":"Intern Med"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/1\/144\/741572\/dc231344.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/1\/144\/741572\/dc231344.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T14:56:54Z","timestamp":1703084214000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/1\/144\/153862\/Metformin-Cimetidine-Drug-Interaction-and-Risk-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,10]]},"published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-1344","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.24415606.v1","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.24415606","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]}}}